Bedrijfsoverzicht
Regeneron Pharmaceuticals, Inc. operates within the healthcare sector as a biotechnology entity, specializing in the discovery, invention, development, manufacturing, and commercialization of medicines designed to treat various diseases globally. The company's portfolio includes product candidates targeting conditions ranging from eye disorders and allergic or inflammatory diseases to cardiovascular, metabolic, neurological, infectious, and rare diseases. This leading biotechnology firm currently maintains a substantial market capitalization of $79.17 billion and generates an annual recurring revenue stream of $14.34 billion based on trailing twelve-month data. With a workforce comprising 15,410 employees, the organization demonstrates significant operational scale, positioning it as a major player capable of sustaining extensive research and development activities while commercializing a diverse pipeline of therapeutic agents worldwide.
Financiële gezondheid
The company reported trailing twelve-month revenue of $14.34 billion, with a corresponding net income of $4.50 billion and EBITDA reaching $4.25 billion. The substantial difference between the revenue figure of $14.34 billion and the net income of $4.50 billion indicates a cost structure where operating expenses, including research and development and sales costs, consume approximately 68.6% of total revenue before reaching the bottom line. Free cash flow stands at $3.26 billion, which provides the firm with considerable financial flexibility to fund ongoing innovation, manage capital allocation, or weather periods of market volatility without compromising operational stability. Profitability metrics reveal a gross margin of 44.6%, an operating margin of 23.1%, and a profit margin of 31.4%, suggesting that while the company maintains high pricing power and efficiency in converting sales to profit, the gap between gross and net margins reflects significant overhead costs inherent in the biotechnology industry. Regarding liquidity and leverage, the company holds $8.61 billion in cash against total debt of $2.97 billion, resulting in a debt-to-equity ratio of 9.51, which suggests a conservative balance sheet structure where cash reserves significantly exceed debt obligations despite the high leverage ratio metric. Short-term liquidity is robust, evidenced by a current ratio of 4.13, indicating that the company possesses ample current assets to cover its short-term liabilities many times over. Management effectiveness is further illuminated by a return on equity of 14.9% and a return on assets of 5.9%, demonstrating the ability to generate substantial returns for shareholders relative to the equity base and efficient utilization of the total asset base to produce earnings.
Waarderingsbeoordeling
Valuation multiples indicate that the stock trades at a trailing P/E ratio of 18.05 and a forward P/E of 14.25, implying that the market expects earnings growth in the future that would allow the forward multiple to justify a lower price relative to anticipated earnings compared to the historical trailing performance. The price-to-book ratio is recorded at 2.46, suggesting that the market assigns a premium to the company's assets and intangible intellectual property that exceeds the sum of its book value by more than two times. Alternative valuation perspectives include a price-to-sales ratio of 5.52 and an enterprise value to EBITDA multiple of 16.77, which provide context on how the market values the company's revenue generation capabilities and cash flow potential relative to its peers. In terms of trading range, the 52-week high is $821.11 and the 52-week low is $476.49, placing the current market position within a wide historical band that reflects significant volatility over the past year. The beta value of 0.40 indicates that the stock's price volatility is substantially lower than the broader market, suggesting a defensive characteristic where the asset is less sensitive to general market movements compared to the average equity.
Growth & Income
Revenue growth year-over-year is recorded at 2.5%, while earnings growth year-over-year stands at -2.6%, indicating that earnings are currently contracting relative to revenue expansion, which implies that top-line growth has not yet translated into proportional bottom-line growth, possibly due to increasing expenses or one-time charges. The company offers a dividend yield of 0.5% with a payout ratio of 8.5%, indicating that the dividend is highly sustainable as it requires a very small fraction of earnings to be distributed to shareholders, leaving the majority of profits available for reinvestment. Given the low payout ratio, the firm retains the vast majority of its earnings to fund its extensive research and development initiatives rather than distributing cash to shareholders. Overall, the growth and income profile presents a scenario of moderate revenue expansion paired with a conservative dividend policy that prioritizes capital retention for long-term scientific advancement over current income distribution.